Insisting on the leading product of anesthetics，together with the mottoof“Healthy and Happyfor Everyone in Every Family”, Yichang Humanwell Healthcarehas become Asia’s largest anesthetics research and production base by striving to enforce innovation-driven strategy and promoting transformation and upgrading itsinternationalization comprehensively in the past five years. Li Jie, presidentof the board of Yichang Huamnwell Healthcare,told the journalist earlier that they will grasp the developing opportunity firmly and focus on the leadinginternational advanced anesthetics technology guided by the spirit of CPC’s 19th National Congress to achieve the Three Steadfastness and develop better and faster.

　　Innovation is a new engine of China’s development. Committed to implementingthe scientific and technological innovation strategy, the company will continue to make the hospital surgery anesthetics as the main line in their future technical research and development, and focus on the leading science and technology. Based on the bigger, stronger and more professional narcotic sedatives, thecompanyisgradually developing general anesthesia, local anesthesia, muscle relaxants, psychotropic drugs, antagonist and medical apparatus and instruments for anesthesiology department, in particular,thoseproducts with independent intellectual property rights, to fill the domestic blank. A series of new national first sort anesthesia drugs are being developed, such as Remimazolam，M6G (morphine-6-glucuronide) and Fospropofol disodium . Once listed,they will be the vital alternative products in the market.

　　Steadfast to push forward the upgradingtransformation, the company’s export base has passed the FDA’s site inspection withzero-defect twice. Thus, its first batch of drugs has been sold abroad,realizingthe “zero-breakthrough” for oral formulation drugs,exportedto Europe and United States. The annual output of 20 tons API (Active Pharmaceutical Ingredient) workshop has passed the site inspection of South Korea and European Union and got the GMP (Good Manufacturing Practice) certificate. International experts and enterprises in pharmaceutical industry have been invited to design the world’s top quality system in accordance with the international standard to verify, evaluate and improve the existing quality system comprehensively. Meanwhile, the upgrading and rebuilding for the workshop of small volume injections and freeze-dried emulsion havebeen launched in all aspects which will reach the standard of United States FDA (Food and Drug Administration) and European Union EMA(European Medicines Agency) after being finished. The company is strivingto achieve the international top standard in all production lines before 2020, ready for competingagainst the growing severe global competition of pharmaceutical market.

　　Firmly stickingto promoting academics, and improvingmarketing innovation, the company plansto break the traditional single sales framework to construct modernized marketing system integrating with access, medicine, market, andsale. Adheringto themarketingconcept of “academic promotion” , it ispromoting its all-round academicsincluding product positioning, clinical research, and education for doctors, market application and academic development. Thecompany has participatedin industry research widely, supplyingthe accuracy market information, spreadingthe advanced academic concepts, and helpingclinicians to learn and master the latest drug use technology and further enhance the level of anesthesia drugs both home and abroad. It aims to realize the continuous growth in various fields of both Chinaand the world, as well ashelp more patients relieve from their pains.